Last updated on July 2019

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)


Brief description of study

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors that have progressed on standard of care therapy will be treated with pembrolizumab.

Clinical Study Identifier: NCT02628067

Find a site near you

Start Over

Merck Sharp & Dohme

North Ryde, Australia
  Connect »

MSD Brasil

Sao Paulo, Brazil
  Connect »

Merck Canada

Kirkland, QC Canada
  Connect »

MSD K.K.

Chiyoda-Ku, Tokyo, Japan
  Connect »

MSD Korea LTD

Seoul, Korea, Republic of
  Connect »

MSD

Mexico City, Mexico
  Connect »

Merck Sharp & Dohme Ltd.

Hoddesdon, United Kingdom
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.